Is ASCLF or QYLD a better dividend investment in 2026?

ASCLF currently yields 110.50% with a 5% 5-year dividend growth rate. QYLD yields 11.92% with -2.1% growth. The better choice depends on your goal: ASCLF offers higher current income.

What is the dividend yield difference between ASCLF and QYLD?

ASCLF has a forward dividend yield of 110.50% ($2.00/share annually). QYLD yields 11.92% ($2.04/share annually). The yield gap is 98.58 percentage points.

Home › Compare › ASCLF vs QYLD

ASCLF vs QYLD: Dividend Comparison 2026

ASCLF yields 110.50% · QYLD yields 11.92%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 ASCLF wins by $5.90M in total portfolio value

INVESTMENT

TIME HORIZON10 years

ASCLF

● Live price

110.50%

Share price

$1.81

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$5.93M

Annual income

$2,132,830.87

Full ASCLF calculator →

QYLD

Global X Nasdaq 100 Covered Call ETF

● Live price

11.92%

Share price

$17.15

Annual div

$2.04

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$25.4K

Annual income

$5,659.31

Full QYLD calculator →

Portfolio growth — ASCLF vs QYLD

📍 ASCLF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	ASCLF	QYLD
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, ASCLF + QYLD cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

ASCLF pays

QYLD pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ASCLF

Annual income on $10K today (after 15% tax)

$9,392.27/yr

After 10yr DRIP, annual income (after tax)

$1,812,906.24/yr

QYLD

Annual income on $10K today (after 15% tax)

$1,013.51/yr

After 10yr DRIP, annual income (after tax)

$4,810.41/yr

At 15% tax rate, ASCLF beats the other by $1,808,095.83/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ASCLF + QYLD for your $10,000?

ASCLF: 50%QYLD: 50%

100% QYLD50/50100% ASCLF

Portfolio after 10yr

$2.98M

Annual income

$1,069,245.10/yr

Blended yield

35.91%

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ASCLF buys

QYLD buys

No recent congressional trades found for ASCLF or QYLD in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricASCLFQYLD

Forward yield	110.50% ✓	11.92%
Annual dividend / share	$2.00	$2.04 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$5.93M	$25.4K ✓
Annual income after 10y	$2,132,830.87 ✓	$5,659.31
Total dividends collected	$5.35M	$27.1K ✓
Payment frequency	quarterly	monthly
Sector	Stock	ETF

Year-by-year: ASCLF vs QYLD ($10,000, DRIP)

Year	ASCLF Portfolio	ASCLF Income/yr	QYLD Portfolio	QYLD Income/yr	Gap
1← crossover	$21,750	$11,049.72	$10,352	$1,192.36	+$11.4K → ASCLF
2	$45,733	$22,460.60	$10,830	$1,347.57	+$34.9K → ASCLF
3	$93,072	$44,137.91	$11,460	$1,539.07	+$81.6K → ASCLF
4	$183,537	$83,949.70	$12,275	$1,777.84	+$171.3K → ASCLF
5	$351,102	$154,717.47	$13,323	$2,078.95	+$337.8K → ASCLF
6	$652,287	$276,608.54	$14,667	$2,463.34	+$637.6K → ASCLF
7	$1,178,220	$480,272.57	$16,396	$2,960.57	+$1.16M → ASCLF
8	$2,071,454	$810,758.34	$18,631	$3,612.97	+$2.05M → ASCLF
9	$3,548,616	$1,332,160.25	$21,548	$4,482.15	+$3.53M → ASCLF
10	$5,929,850	$2,132,830.87	$25,398	$5,659.31	+$5.90M → ASCLF

ASCLF vs QYLD: Complete Analysis 2026

ASCLF — Stock

Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China and internationally. The company offers Ritonavir oral tablet, a pharmacokinetic booster of various oral antiviral drugs targeting viral proteases and a component of the approved oral antiviral drug Paxlovid; ASCLEVIR and GANOVO for the treatment of Hepatitis C virus. It is also developing ASC22 for treating chronic hepatitis B (CHB) and human immunodeficiency virus functional cure; ASC42 for chronic hepatitis B functional cure; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, ASC42, ASC43F FDC, ASC44F FDC, and ASC45F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma, drug resistant breast cancer, and KRAS mutant non-small cell lung cancer; ASC61 and ASC63 for advanced solid tumors; ASC60 to treat solid tumors; and ASC40 for the treatment of acne, Ascletis Pharma Inc. was founded in 2013 and is headquartered in Hangzhou, the People's Republic of China.

Full ASCLF Calculator →

QYLD — ETF

The Global X Nasdaq 100 Covered Call ETF (QYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Nasdaq-100 BuyWrite V2 Index.

Full QYLD Calculator →

📬

Get this ASCLF vs QYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ASCLF vs SCHD ASCLF vs JEPI ASCLF vs O ASCLF vs KO ASCLF vs MAIN ASCLF vs XYLD ASCLF vs JEPQ ASCLF vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.